Critical Review of Current Treatment Strategies for Advanced Hormone Insensitive Breast Cancer

REFERENCES

• Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-Term Follow-up of Patients with Complete Remission Following Combination Chemotherapy for Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 2197–2205
   PubMed Web of Science ®Google Scholar
• Hortobagyi G.N. Can We Cure Limited Metastatic Breast Cancer?. J. Clin. Oncol. 2002; 20: 620–623
   PubMed Web of Science ®Google Scholar
• Falkson G., Gelman R.S., Leone L., Falkson C.I. Survival of Premenopausal Women with Metastatic Breast Cancer. Long-Term Follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B Studies. Cancer 1990; 66(7)1621–1629
   PubMed Web of Science ®Google Scholar
• Nabholtz J.M., Senn H.J., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., Vandenberg T.A., Rapoport B., Rosso R., Trillet-Lenoir V., Drbal J., Molino A., Nortier J.W., Richel D.J., Nagykalnai T., Siedlecki P., Wilking N., Genot J.Y., Hupperets P.S., Pannuti F., Skarlos D., Tomiak E.M., Murawsky M., Alakl M., Aapro M. Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients with Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy. J. Clin. Oncol. 1999; 17(5)1413–1424
   PubMed Web of Science ®Google Scholar
• Bishop J.F., Dewar J., Toner G.C., Smith J., Tattersall M.H.N., Olver I.N., Ackland S., Kennedy I., Goldstein D., Gurney H., Walpole E., Levi J., Stephenson J., Canetta R. Initial Paclitaxel Improves Outcome Compared to CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer. J. Clin. Oncol. 1999; 17: 2355–2364
   PubMed Web of Science ®Google Scholar
• Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N. Engl. J. Med. 2001; 344(11)783–792
   PubMed Web of Science ®Google Scholar
• Geels P., Eisenhauer E., Bezjak A., Zee B., Day A. Palliative Effect of Chemotherapy: Objective Tumor Response Is Associated with Symptom Improvement in Patients with Metastatic Breast Cancer. J. Clin. Oncol. 2000; 18: 2395–2405
   PubMed Web of Science ®Google Scholar
• Ganz P.A., Moinpour C.M., Cella D.F., Fetting J.H. Quality of Life Assessment in Cancer Clinical Trials: A Status Report. J. Natl Cancer Inst. 1992; 84: 994–995
   PubMed Web of Science ®Google Scholar
• Garufi C., Nistico C., Brienza S., Vaccaro A., D'Ottavio A., Zappala A.R., Aschelter A.M., Terzoli E. Single-Agent Oxaliplatin in Pretreated Advanced Breast Cancer Patients: A Phase II Study. Ann. Oncol. 2001; 12(2)179–182
   PubMed Web of Science ®Google Scholar
• Sledge G.W., Jr., Antman K.H. Progress in Chemotherapy for Metastatic Breast Cancer. Semin. Oncol. 1992; 19(3)317–332
   PubMed Web of Science ®Google Scholar
• Sledge G.W., et al. J. Clin. Oncol., (In Press)
   Google Scholar
• Schwartzberg L., Birch R., Weaver C., Woods J., Canale C., Ma L., Tauer K., Schnell F., Iannotti N., West W. Randomized Trial of Simultaneous (SIM) Vs. Sequential (SEQ) Doxorubicin (A) and Docetaxel (T) in Patients (Pts) with Metastatic Breast Cancer (Mbc). Proc. Am. Soc. Clin. Onocol. 2000; 19: 72a, (#. 278)
   Google Scholar
• Joensuu H., Holli K., Heikkinen M., Suonio E., Aro A.R., Hietanen P., Huovinen R. Combination Chemotherapy Versus Single-Agent Therapy as First- and Second-Line Treatment in Metastatic Breast Cancer: A Prospective Randomized Trial. J. Clin. Oncol. 1998; 16: 3720–3730
   PubMed Web of Science ®Google Scholar
• Heidemann E., Stoeger H., Souchon R., Hirschmann W.D., Bodenstein H., Oberhoff C., Fischer J., Schulze M., Clemens M., Andreesen R., Mahlke M., Konig M., Scharl A., Gruener A., Kaufmann M. Balance of Time to Progression, Quality of Life, and Overall Survival: More Gain from Treatment in Single Agent Treatment with Mitoxantrone (N) Than with the Combination of Fluorouracil, Epirubicin, Cyclophosphamide (Fec). Proc. Am. Soc. Clin. Oncol. 2000; 19: 74a, (#. 284)
   Google Scholar
• Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna E., Pistotti V., Tinazzi A., Liberati A. Cytotoxic and Hormonal Treatment for Metastatic Breast Cancer: A Systematic Review of Published Randomized Trials Involving 31,510 Women. J. Clin. Oncol. 1998; 16: 3439–3460
   PubMed Web of Science ®Google Scholar
• Nabholtz J.M., Gelmon K., Bontenbal M., Spielmann M., Catimel G., Conte P., Klaassen U., Namer M., Bonneterre J., Fumoleau P., Winograd B. Multicenter, Randomized Comparative Study of Two Doses of Paclitaxel in Patients with Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14(6)1858–1867
   PubMed Web of Science ®Google Scholar
• Winer E., Berry D., Duggan D., Henderson I.C., Cirrincione C., Cooper R., Norton L. Failure of Higher Dose Paclitaxel to Improve Outcome in Patients with Metastatic Breast Cancer—Results from CALGB 9342. Proc. Am. Soc. Clin. Oncol. 1998; 17: 101a, (# 388)
   Google Scholar
• Holmes F.A., Valero V., Buzdar A.U., Booser D.J., Winn R., Tolcher A., Seidman A., Goodwin W., Bearden J., Baysinger L., Hortobagyi G.N., Arbuck S.A. Final Results: Randomized Phase III Trial of Paclitaxel by 3-Hr Versus 96-Hr Infusion in Patients with Metastatic Breast Cancer. The Long and Short of It. Proc. Am. Soc. Clin. Oncol. 1998; 17: 110a, abs 426
   Google Scholar
• Peretz T., Sulkes A., Chollet P., Gelmon K., Parideans R., Gorbonuva V., Catimel G., Kuhnle H., ten Bokkel Huinink W., Khayat D., Ditrich C., Klaasen U., Bergh J., Wilking N., Nabholtz J.M., Calabresi F., Tubiana-Hulin M., Chazard M., Gallant G., Diergarten K., Westberg R., Bogaert J., Renard J., Weil C. A Multicenter Randomized Study of Two Schedules of Paclitaxel in Patients with Advanced Breast Cancer. Eur. J. Cancer 1995; 31(975)S75–S75
   Google Scholar
• Smith R.E., Brown A.M., Mamounas E.P., Anderson S.J., Lembersky B.C., Atkins J.H., Shibata H.R., Baez L., DeFusco P.A., Davila E., Tipping S.J., Bearden J.D., Thirlwell M.P. Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients with Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol. 1999; 17(11)3403–3411
   PubMed Web of Science ®Google Scholar
• Seidman A.D., Hudis C.A., Albanel J., Tong W., Tepler I., Currie V., Moynahan M.E., Theodoulou M., Gollub M., Baselga J., Norton L. Dose-Dense Therapy with Weekly 1-Hour Paclitaxel Infusions in the Treatment of Metastatic Breast Cancer. J. Clin. Oncol. 1998; 16: 3353–3361
   PubMed Web of Science ®Google Scholar
• Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Multicenter Phase II Trial of Weekly Paclitaxel in Women with Metastatic Breast Cancer. J. Clin. Oncol. 2001; 19: 4216–4223
   PubMed Web of Science ®Google Scholar
• Burstein H.J., Manola J., Younger J., Parker L.M., Bunnell C.A., Scheib R., Matulonis U.A., Garber J.E., Clarke K.D., Shulman L.N., Winer E.P. Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer. J. Clin. Oncol. 2000; 18: 1212–1219
   PubMed Web of Science ®Google Scholar
• Valero V., Jones S.E., Von Hoff D.D., Booser D.J., Mennel R.G., Ravdin P.M., Holmes F.A., Rahman Z., Schottstaedt M.W., Erban J.K., Esparza-Guerra L., Earhart R.H., Hortobagyi G.N., Burris H.A. A Phase II Study of Docetaxel in Patients with Paclitaxel-Resistant Metastatic Breast Cancer. J. Clin. Oncol. 1998; 16: 3362–3368
   PubMed Web of Science ®Google Scholar
• Seidman A.D. Dose Intensity. Breast Dis. 2001; 14: 1–89
   PubMedGoogle Scholar
• Stadtmauer E.A., O'Neill A., Goldstein L.J., Crilley P.A., Mangan K.F., Ingle J.N., Brodsky I., Martino S., Lazarus H.M., Erban J.K., Sickles C., Glick J.H. Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy Plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med. 2000; 342(15)1069–1076
   PubMed Web of Science ®Google Scholar
• Bezwoda W.R., Seymour L., Dansey R.D. High-Dose Chemotherapy with Hematopoietic Rescue as Primary Treatment for Metastatic Breast Cancer: A Randomized Trial. [Retraction in J. Clin. Oncol. 2001 Jun 1, 19(11):2973]. J. Clin. Oncol. 1995; 13(10)2483–2489
   PubMed Web of Science ®Google Scholar
• Weiss R.B., Gill G.G., Hudis C.H. An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications. J. Clin. Oncol. 2001; 19: 2771–2777
   PubMed Web of Science ®Google Scholar
• Seidman A.D. One-Hour Paclitaxel via Weekly Infusion: Dose-Density with Enhanced Therapeutic Index. Oncology 1998; 12(1 Suppl. 1)19–22
   PubMed Web of Science ®Google Scholar
• Blum J.L., Jones S.E., Buzdar A.U., Lo Russo P.M., Kutler I., Vogel C., Osterwalder B., Burger H.-U., Brown C.S., Griffin T. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer. J. Clin. Oncol. 1999; 17: 485–493
   PubMed Web of Science ®Google Scholar
• Blum J.L., Dieras V., Lo Russo P.M., Horton J., Rutman O., Buzdar A., Osterwalder B. Multicenter, Phase II Study of Capecitabine in Taxane-Pretreated Metastatic Breast Carcinoma Patients. Cancer 2001; 92(7)1759–1768
   PubMed Web of Science ®Google Scholar
• Thuss-Patience P.C., von Minckwitz G., Lück H.J., Jonat W., Kölbl H., Kieback D., Kuhn W., Schindler A.E., Jänicke F., Mohrmann S., Floemer F., Frings S., Reichardt P. Capecitabine: A New Standard in Metastatic Breast Cancer Recurring After Anthracycline and Taxane-Containing Chemotherapy? Results of a Multicenter Phase II Trial. Proc. Am. Soc. Clin. Oncol. 2001; 20: 66b, (#. 2012)
   Google Scholar
• O'Shaughnessy J., Miles D., Vukeluja S., Moiseyenko V., Ayoub J.-P., Cervantes G., Fumolean P., Jones S., Lui W.-Y., Mauriac L., Twelves C., Van Hazel G., Verma S., Leonard R. Superior Survival with Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer: Phase III Trial Results. J. Clin. Oncol. 2002; 2812–2823
   PubMed Web of Science ®Google Scholar
• Blackstein M., Vogel C.L., Ambinder R., Cowan J., Iglesias J., Melemed A. Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial. Oncology 2002; 62(1)2–8
   PubMed Web of Science ®Google Scholar
• Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A.L. Advanced Breast Cancer: A Phase II Trial with Gemcitabine. J. Clin. Oncol. 1995; 13(11)2731–2736
   PubMed Web of Science ®Google Scholar
• Spielmann M., Llombart-Cussac A., Kalla S., Espie M., Namer M., Ferrero J.-M., Dieras V., Fumoleau P., Cuvier C., Perrocheau G., Ponzio A., Kayitaire L., Pouillart P. Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer. Oncology 2001; 60: 303–307
   PubMed Web of Science ®Google Scholar
• Possinger K., Kaufmann M., Coleman R., Stuart N.S., Helsing M., Ohnmacht U., Arning M. Phase II Study of Gemcitabine as First-Line Chemotherapy in Patients with Advanced or Metastatic Breast Cancer. Anti-Cancer Drugs 1999; 10(2)155–162
   PubMed Web of Science ®Google Scholar
• Brodowicz T., Koestler W.J., Tomek S., Vaclavik I., Herscovici V., Wiltschke C., Steger G.G., Zielinski C.C. Monotherapy with Docetaxel in Second- or Third-Line Treatment of Anthracycline-Resistant Metastatic Breast Cancer. Anti-Cancer Drugs 2000; 11(3)149–153
   PubMed Web of Science ®Google Scholar
• Valerio M.R., Cicero G., Armata M.G., Bajardi E., Crosta A., Badalamenti G., Arcara C., Agosta G., Vieni S., Latteri F., Russo A., Gulotta G., Gebbia N. Gemcitabine (G) in Pretreated Breast Cancer (BC). Proc. Am. Soc. Clin. Oncol. 2001; 20: 51b, (#. 1953)
   Google Scholar
• Seidman A.D. The Evolving Role of Gemicitabine in the Management of Breast Cancer. Oncology 2001; 60: 189–198
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy, J.A.; Vukelja, S.; Marsland, T.; Kimmel, G.; Ratnam, S.; Pippen, J.E. Gemcitabine and Trastuzumab (Herceptin) for HER2-Positive Metastatic Breast Cancer: Preliminary Results of a Phase II Study. 24th San Antonio Breast Cancer Symposium San Antonio, TX, Dec 10–13, 2001; Poster Presentation 523.
   Google Scholar
• Domenech G.H., Vogel C.L. A Review of Vinorelbine in the Treatment of Breast Cancer. Clin. Breast Cancer 2001; 2(2)113–128
   PubMedGoogle Scholar
• Havlin K.A., Ramirez M.J., Legler C.M., Harris L.N., Matulonis U.A., Hohneker J.A., Hayes D.F., Winer E.P. Inability to Escalate Vinorelbine Dose Intensity Using a Daily ×3 Schedule with and without Filgrastim in Patients with Metastatic Breast Cancer. Cancer Chemother. Pharmcol. 1999; 43(1)68–72
   PubMed Web of Science ®Google Scholar
• Fumoleau P., Delgado F.M., Delozier T., Monnier A., Gil Delgado M.A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M.T. Phase II Trial of Weekly Intravenous Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy. J. Clin. Oncol. 1993; 11: 1245–1252
   PubMed Web of Science ®Google Scholar
• Romero A., Rabinovich M.G., Vallejo C.T., Perez J.E., Rodriguez R., Cuevas M.A., Machiavelli M., Lacava J.A., Langhi M., Romero Acuna L. Vinorelbine as First-Line Chemotherapy for Metastatic Breast Carcinoma. J. Clin. Oncol. 1994; 12: 336–341
   PubMed Web of Science ®Google Scholar
• Sorio R., Roieux I., Galligioni E., Freschi A., Colussi A.M., Crivellari D., Saracchini S., Monfardini S. Pharmacokinetics and Tolerance of Vinorelbine in Elderly Patients with Metastatic Breast Cancer. Eur. J. Cancer 1997; 33: 301–303
   PubMed Web of Science ®Google Scholar
• Vogel C., O'Rourke M., Winer E., Hochster H., Chang A., Adamkiewicz B., White R., McGuirt C. Vinorelbine as First-Line Chemotherapy for Advanced Breast Cancer in Woman 60 Years of Age or Older. Ann. Oncol. 1999; 10: 397–402
   PubMed Web of Science ®Google Scholar
• Fazeny B., Zifko U., Meryn S., Huber H., Grisold W., Dittrich C. Vinorelbine-Induced Neurotoxicity in Patients with Advanced Breast Cancer Pretreated with Paclitaxel—A Phase II Study. Cancer Chemother. Pharmacol. 1996; 39: 150–156
   PubMed Web of Science ®Google Scholar
• Ellis G.K., Gralow J.R., Pierce H.I., Williams M.A., Livingston R.B. Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy with Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I–II Study of Doxorubicin-Treated Patients. J. Clin. Oncol. 1999; 17: 1407–1412
   PubMed Web of Science ®Google Scholar
• Romero Acuña L., Langhi M., Pérez J., Romero Acuña J., Machiavelli M., Lacava J., Vallejo C., Romero A., Fasce H., Ortiz E., Grasso S., Amato S., Rodríguez R., Barbieri M., Leone B. Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer. J. Clin. Oncol. 1999; 17: 74–81
   PubMed Web of Science ®Google Scholar
• Burstein H.J., Kuter I., Campos S.M., Gelman R.S., Tribou L., Parker L.M., Manola J., Younger J., Matulonis U., Bunnell C.A., Partridge A.H., Richardson P.G., Clarke K., Shulman L.N., Winer E.P. Clinical Activity of Trastuzumab and Vinorelbine in Women with HER2-Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 2001; 19(10)2722–2730
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p 185HER2 Mononclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.L. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 1999; 17: 2639–2648
   PubMed Web of Science ®Google Scholar
• Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphey M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 2002; 20(3)719–726
   PubMed Web of Science ®Google Scholar
• Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M., Murphy M., Stewart S.J., Keefe D. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. J. Clin. Oncol. 2002; 20(5)1215–1221
   PubMed Web of Science ®Google Scholar
• Vogel C.L., Cobleigh M., Tripathy D., Mass R., Murphy M., Stewart S.J. Superior Outcomes with Herceptin (Trastuzumab) (H) in Fluorescence In Situ Hybridization (Fish)-Selected Patients. Proc. Am. Soc. Clin. Oncol. 2001; 20: 22b, (#. 86)
   Google Scholar
• Mass R.D., Press M., Anderson S., Murphy M., Slamon D. Improved Survival Benefit from Herceptin (Trastuzumab) in Patients Selected by Fluorescence In Situ Hybridization (Fish). Proc. Am. Soc. Clin. Oncol. 2001; 21, (#. 85)
   Google Scholar
• Leyland-Jones B., Hemmings F., Arnold A., Gelmon K., Verma S., Ayoub J.-P. Pharmacokinetics and Safety of Herceptin, Administered with Paclitaxel Every 3 Weeks, in Women with Metastatic Breast Cancer. Breast Cancer Res. Treat. 2000; 64(1)124, (#. 534)
   Google Scholar
• Gelmon K., Arnold A., Verma S., Ayoub J., Hemmings F., Leyland-Jones B. Pharmacokinetics (PK) and Safety of Trastuzumab (Herceptin) When Administered Every Three Weeks to Women with Metastatic Breast Cancer. Proc. Am. Soc. Clin. Oncol. 2001; 20: 69a, (#. 271)
   Google Scholar
• Theodoulou M., Campos S., Welles L., Almonte A., Batist G., Winer E., Hudis C. Cardiac Safety and Efficacy of TLC D99 (D, Myocet™ and Herceptin® (H) in Advanced Breast Cancer (ABC). Breast Cancer Res. Treat. 2001; 69(3)283, (#. 427)
   Web of Science ®Google Scholar
• Pestalozzi B.C., Brignoli S. Trastuzumab in SCF. J. Clin. Oncol. 2000; 18: 2350–2351
   Google Scholar
• Hortobagyi G.N., Theriault R.L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J.F., Seaman J., Knight R.D., Heffernan M., Reitsma D.J., Kennedy I., Allan S.G., Mellars K. The Protocol 19 Aredia Breast Cancer Study Group. Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases: Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 1996; 335: 1785–1791
   PubMed Web of Science ®Google Scholar
• Burstein H.J., Gelber S., Guadagnoli E., Weeks J.C. Use of Alternative Medicine by Women with Early-Stage Breast Cancer. N. Engl. J. Med. 1999; 340(22)1733–1739
   PubMed Web of Science ®Google Scholar
• Norris B., Pritchard K.I., James K., Myles J., Bennett K., Marlin S., Skillings J., Findlay B., Vandenberg T., Goss P., Latreille J., Rudinskas L., Lofters W., Trudeau M., Osoba D., Rodgers A. Phase III Comparative Study of Vinorelbine Combined with Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J. Clin. Oncol. 2000; 18(12)2385–2394
   PubMed Web of Science ®Google Scholar
• Rha S.Y., Jeung H., Kim Y., Park J., Chung H., Roh J., Min J., Kim B., Jang W. Efficacy of Gemcitabine as a Salvage Treatment in Breast Cancer Patients Refractory to Anthracycline and Paclitaxel Based Regimen. Proc. Am. Soc. Clin. Oncol. 2002; 21: 57b, (#. 2038)
   Google Scholar